Tumour infiltrating B cells discriminate checkpoint blockade-induced responses
Authors
Valpione, SaraCampana, L. G.
Weightman, John
Salih, Zena
Galvani, Elena
Mundra, Piyushkumar A
De Rosa, F.
Gupta, Avinash
Serra-Bellver, Patricio
Lorigan, Paul C
Germetaki, Theodora
Dynowski, Marek
Kitcatt, Stephen
Sahoo, Sudhakar
Lee, Dave
Dhomen, Nathalie
Lord, G.
Marais, Richard
Affiliation
Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, United Kingdom; The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, United Kingdom.Issue Date
2022
Metadata
Show full item recordAbstract
Background: Immune cell-driven anti-cancer activity is paramount for effective responses to checkpoint inhibitors (ICB). However, the contribution of the different immune cell subsets in the circulation and within the tumour is poorly understood. Materials and methods: To elucidate the role of the different cell subsets in anti-tumour responses elicited by ICB, we performed single-cell analysis of the transcriptome and surface proteome of paired pre- and early on-treatment metastatic melanoma tumour biopsies and matched peripheral blood mononuclear cell samples. We next compared the survival of metastatic melanoma patients treated with ICB according to the abundance of pre-treatment tumour-infiltrating B cell clonotypes. Results: We identified cell clusters associated with disease control or progression, defined differential expression of biological pathways likely involved in the immune awakening against the tumour and examined how cell-cell communication patterns between the tumour cell subsets change during treatment. Furthermore, we discovered that B cells (immunoglobulin expression and abundance of B cell clonotypes) discriminate the clinical response after ICB and propose that B cells likely contribute to anti-tumour immunity by antigen presentation through major histocompatibility complex molecules. Finally, we demonstrated that the abundance of tumour-infiltrating B cell clonotypes at baseline identifies two distinct risk groups, a finding that we confirmed in an independent cohort. Conclusions: Our exploratory translational study provides new insights on the mechanistic role of B cells in anti-melanoma immunity during treatment with ICB. Additionally, we support pre-treatment B cell tumour infiltration as a promising prognostic biomarker to be further validated as a tool for clinical risk stratification.Citation
Valpione S, Campana LG, Weightman J, Salih Z, Galvani E, Mundra PA, et al. Tumour infiltrating B cells discriminate checkpoint blockade-induced responses. European journal of cancer (Oxford, England : 1990). 2022 Oct 5;177:164-74. PubMed PMID: 36347135. Epub 2022/11/09. eng.Journal
European Journal of CancerDOI
10.1016/j.ejca.2022.09.022PubMed ID
36347135Additional Links
https://dx.doi.org/10.1016/j.ejca.2022.09.022Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2022.09.022
Scopus Count
Collections
Related articles
- Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
- Authors: Bochem J, Zelba H, Spreuer J, Amaral T, Wagner NB, Gaissler A, Pop OT, Thiel K, Yurttas C, Soffel D, Forchhammer S, Sinnberg T, Niessner H, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler TK, Löffler MW, Weide B, Wistuba-Hamprecht K
- Issue date: 2021 Dec
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
- Authors: Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C
- Issue date: 2018 Sep
- Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
- Authors: Fröhlich A, Loick S, Bawden EG, Fietz S, Dietrich J, Diekmann E, Saavedra G, Fröhlich H, Niebel D, Sirokay J, Zarbl R, Gielen GH, Kristiansen G, Bootz F, Landsberg J, Dietrich D
- Issue date: 2020 Feb
- B cells and tertiary lymphoid structures promote immunotherapy response.
- Authors: Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA
- Issue date: 2020 Jan
- Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade.
- Authors: Chen S, McMiller TL, Soni A, Succaria F, Sidhom JW, Cappelli LC, Casciola-Rosen LA, Morales IR, Sankaran P, Berger AE, Deutsch JS, Zhu QC, Anders RA, Hooper JE, Pardoll DM, Lipson EJ, Taube JM, Topalian SL
- Issue date: 2024 Mar 5